SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-026537
Filing Date
2018-04-27
Accepted
2018-04-27 16:06:58
Documents
2
Period of Report
2018-04-20

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 5301
2 EX-24 DOCUMENT attachment1.htm EX-24 4134
  Complete submission text file 0001209191-18-026537.txt   10836
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences

Mailing Address C/O INTELLIA THERAPEUTICS 40 ERIE STREET STE 130 CAMBRIDGE MA 02139
Business Address
SCHIERMEIER ANDREW (Reporting) CIK: 0001738456 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37766 | Film No.: 18783883